Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity (Tables)

v3.23.3
Stockholders’ Equity (Tables)
9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Schedule of Share-Based Compensation Expense The following table sets forth share-based compensation expense included in the condensed consolidated statements of operations:
Three Months Ended September 30,
(in thousands)
2023 2022
Cost of revenue 26  17 
Research and development 357  216 
Sales and marketing 431  300 
General and administrative 770  642 
Share-based compensation expense $ 1,584  $ 1,175 

Nine Months Ended September 30,
(in thousands)
2023 2022
Cost of revenue 74  33 
Research and development 1,009  701 
Sales and marketing 1,277  639 
General and administrative 2,176  1,581 
Share-based compensation expense $ 4,536  $ 2,954 
Share-based compensation expense by type of share-based award is summarized below:
Three Months Ended September 30,
(in thousands)
2023 2022
Stock options 233  260 
RSAs and RSUs 1,308  860 
ESPP 43  55 
$ 1,584  $ 1,175 
Nine Months Ended September 30,
(in thousands)
2023 2022
Stock options 747  830 
RSAs and RSUs 3,612  1,957 
ESPP 177  167 
$ 4,536  $ 2,954 
Total unrecognized compensation expense by type of award and the weighted-average remaining requisite period over which such expense is expected to be recognized (in thousands, unless otherwise noted):
Years Ended September 30, 2023
Unrecognized Expense Remaining Weighted-Average Recognition Period (in years)
Stock options $ 1,208  1.82
RSAs and RSUs $ 8,187  1.94
Schedule of Stock Option Activity
Stock option activity under the Company’s current and previous plans during the nine months ended September 30, 2023 is summarized below:
Stock Options Weighted-average
Exercise price
per share
Weighted-average
Remaining Contractual Life (in years)
Intrinsic
Value(1)
(in thousands)
Outstanding at December 31, 2022 1,398,286  $ 8.69 
Granted 111,107  $ 8.10 
Exercised (20,000) $ 1.82 
Forfeited or expired (4,374) $ 41.52 
Outstanding at September 30, 2023 1,485,019  $ 8.64  5.69 $ 1,867 
Exercisable at September 30, 2023 1,258,707  $ 8.29  5.10 $ 1,867 
Vested and expected to vest at September 30, 2023 1,485,019  $ 8.64  5.69 $ 1,867 
(1) Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the option exercise price of in-the-money options.
Schedule of Restricted Stock Activity
Restricted stock award ("RSA") activity for the nine months ended September 30, 2023 is summarized below:
Restricted Stock Awards Weighted - Average
Grant
Date Fair Value
Outstanding at December 31, 2022 684,389  $ 11.10 
Vested (270,042) $ 10.06 
Forfeited (5,395) $ 12.51 
Outstanding at September 30, 2023 408,952  $ 11.78 
Restricted Stock Unit Activity
Restricted stock unit ("RSU") activity for the nine months ended September 30, 2023 is summarized below:
Restricted Stock Units Weighted - Average
Grant
Date Fair Value
Outstanding at December 31, 2022 13,146  $ 11.41 
Granted 766,625  $ 8.11 
Vested (13,660) $ 8.73 
Outstanding at September 30, 2023 766,111  $ 8.15 
Schedule of Common Stock Warrants Warrant activity for the nine months ended September 30, 2023 is summarized below:
Shares Weighted - Average
Exercise
Price
Outstanding at December 31, 2022 36,554  $ 16.23 
Expired (36,554) $ 16.23 
Outstanding at September 30, 2023 —  —